The document summarizes the anti-diabetic pharmaceuticals market in India. It finds that the market is valued at INR XX units and is expected to grow at a CAGR of m% until 20--, driven by an increasing aging population and number of diabetic patients. However, the market faces challenges from price regulations and alternative treatments. It also profiles major public and private companies and initiatives by the Indian government to boost diabetes care.

1. Insert Cover Image using Slide Master View
Do not distort
Anti-Diabetic Pharmaceuticals Market - India
March 2012

2. Executive Summary
Global Market of Anti-diabetic pharmaceuticals is expected to growth at a CAGR of X% for 2010
– 2015 period
Market Anti-diabetic pharmaceuticals market in India is valued at INR xx units in 20--
Market is expected to grow at a CAGR of m% from 20-- to 20--
Anti-diabetes therapeutic segment is the second fastest growing segment, after oncology
Drivers: Challenges:
Increase in the number of diabetic Price regulation in insulin market
Drivers and
Challenges
patients
LE
Introduction of newer and better drugs
Increasing aging population
P
Use of complementary and alternative
medicines
Maintainence of healthy lifestyle to avoid
diabetes
Drug
policies covering diabetes
Phases of clinical trial
M
Comprehensive health insurances
SA
Regulation and Approval and licensing of drugs
Patents Patents
Public Companies Private Companies
Company A Company G
Company B Company H
Competition Company C Company I
Company D Company J
Company E
Company F
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 2

3. •Introduction
•Market Overview
•Drivers & Challenges
•Government Initiatives
•Market Value Chain, Regulation and
Patents
•Competition
•Strategic recommendation
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 3

4. India’s diabetes market is poised to grow over the coming
years
Indian Market – Overview Market Size and Growth
• India is considered to be one of the most lucrative
diabetes markets in the world INR bn
• Anti-diabetics represent the second fastest growing y% F
therapeutic segment among all the segments ,after 40 E
D
oncology 30 B C
• Market is expected to grow from INR A bn to INR F bn A
in 20--, at a CAGR of y% 20
• Biguanides, Gliclazide, Gliclazide with metformine, 10
Rosiglitazone and Pioglitazone are the top selling drugs
in Indian market
• Human Mixard 30/70 is the largest selling insulin in
Indian market
It showed largest growth among the top 10 brands in Indian
PLE 0
20-- 20--e 20--e 20--e 20--e 20--e
M
Pharmaceutical market
A
Growth in therapeutic segments(2010) Market Segmentation
oncology
diabetes
0 5 10 15 20 25
b
30
S35
a
%
X1
Drugs
Insulin
Y2
CVS c
X2
CNS d
Y1
respiratory e
pain f
gastro g
anti-infectives h
Source:
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 4

5. Drivers & Challenges
Challenges
Drivers Price regulation in insulin market
Increase in the number of diabetic Competition from complementary and
patients alternative medicines
Introduction of newer and better Maintainence of healthy lifestyle to
drugs avoid diabetes
Increasing aging population
Increase in health insurances
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 5

6. Various initiatives taken by the government is providing a
boost to this market
• ICDC ,registered under Planning Commission, Government of India, is the only organisation in
India providing doorstep diabetes care
• ICDC implements National Doorstep Diabetes Identification and follow-up programme
through Grass Root Level NGOs all over India
Indian Council for • ICDC affiliates NGOs as Partner Organisation and reach people who are suffering with Diabetes and help
Diabetic Care them to control diabetes and live without any complications
• ICDC provides free glucometer and 100 Strips to the NGOs to start identifying the diabetes patients even
in villages
• ICDC is making efforts to provide medical insurance to the diabetes patients through Government of India
LE
as in the case of family planning insurance scheme
MP
• National Programme for prevention and Control of Diabetes, Cardiovascular diseases and
Stroke (NPCDCS) was started in 2008,with the objective of prevention, diagnosis and early
NPCDCS
management of diabetes
SA
• It is already being implemented in 100 most backward and remote districts spread across 21 states
• Indian Government plans to extend this programme to all the 650 districts of the country under the 12th
five year plan
• National Rural Health Mission is providing services for diabetes care in rural India
NRHM • Seeks to provide effective healthcare to rural population throughout the country with special
focus on 18 states
Source:
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 6

7. Major Private Companies - Summary
PAT
1,000
A Size of the Bubble represents Total Assets
0
in INR XX
-1,000
-2,000
-3,000 B
PLE
-4,000
-5,000
-6,000
-7,000 SAM
-8,000
-9,000
C
-10,000
-11,000 Revenue
-500,000 0 500,000 1,000,000 1,500,000 2,000,000 2,500,000 3,000,000 3,500,000
A B C
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 7

8. Public: Domestic Company – A Company (1/3)
Company Information Offices and Centres – India
X Road
Corporate Address
Bangalore
Tel No. +91 xx xxxxx xxxxx
Fax No. +91 xx xxxxx xxxxx
LE
Website www.ppp.com
P
Year of Incorporation 19--
M
Ticker Symbol xxxxxx
A
Stock Exchange NNN
Products and Services
Category Products/Services
S City A
Head Office
CVD, CNS, respiratory, dermatology, Key People
Pharmaceutical orthopedics, nutritional, urology, anti-
infectives Name Designation
Infectious diseases, metabolic diseases, Person M Founder
Molecule
inflammatory/respiratory diseases, and Person N CFO
Development
oncology
Person O Head
Person Q President
Source:
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 8

9. Public: Domestic Company – A Company (2/3)
Financial Snapshot Key Ratios
Particulars y-o-y change 20-- 20-- 20-- 20--
Revenue Revenue Profit
INR mn INR mn Profitability Ratios
q Profit / Loss
t r p Operating Margin
s Net Margin
s
n
r Profit Before Tax Margin
LE
n p Return on Equity
m o 0
q t Return on Capital Employed
0 -m
P
Return on Working Capital
20-- 20-- 20-- 20-- Return on Assets
M
Financial Summary Return on Fixed Assets
Cost Ratios
• The company incurred a net loss of INR xx mn in FY 20--, as
compared to net profit of INR yy mn in FY 20--
• The company reported total income of INR xx bn in FY 20--,
registering an increase of yy per cent over FY 20--
• The company earned an operating margin of x per cent in FY 20-- a
SA Operating costs (% of Sales)
Administration costs (% of
Sales)
Interest costs (% of Sales)
Liquidity Ratios
Current Ratio
decrease of y percentage points over FY 20--
Cash Ratio
• The company reported debt to equity ratio of x in FY 20--, an Leverage Ratios
increase of y per cent over FY 20-- Debt to Equity Ratio
Debt to Capital Ratio
Financial Summary
Interest Coverage Ratio
Indicators Present Value Efficiency Ratios
Market Capitalization (INR) X mn Fixed Asset Turnover
Total Enterprise Value (INR) Y mn Asset Turnover
Current Asset Turnover
EPS (INR) Z mn
Working Capital Turnover
PE Ratio (Absolute) A Capital Employed Turnover
Source: Improved Decline
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 9

10. Public: Domestic Company – A Company (3/3)
Key Business Segments Key Geographic Segments
m n o x y z
x
x x
LE
x x
x x y
x y y
y
z y z y z
y
z
y
MP z
20--
z
20--
z
20--
z
20--
A
20-- 20-- 20-- 20--
Key Recent Developments
Overview
Description S News
• Company A is an integrated research based company that produces a wide range of generic medicines
• Serves customers in over 100 countries with manufacturing facilities in several countries
• Launched Drug M for the treatment of diabetes
Diabetes Management
• Also manufactures Insulin N under its Diabetes management segment
• Is making consistent effort for continual improvement in rural areas with respect to accessibility of
Key Initiatives medicines
Source:
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 10

11. Thank you for the attention
The Anti-Diabetic Pharmaceuticals Market – India report is part of Netscribes’ Healthcare
Industry Series.
For more detailed information or customized research requirements please contact:
Tamojit Roy
E-Mail: sales@netscribes.com
Netscribes (India) Pvt. Ltd. is dedicated to disseminating information and providing quick insights on “hot” industries in India and other
emerging markets. Track our new releases and major updates in these industries on
About Netscribes
Netscribes is a knowledge-consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment &
business research, business & corporate intelligence, content-management services, and knowledge-software services. At its core lies a true
value proposition that draws upon a vast knowledge base. Netscribes is a one-stop shop designed to fulfil clients’ profitability and growth
objectives.
Disclaimer: This report is published for general information only. Although high standards have been used the preparation, Research on India,
Netscribes (India) Pvt. Ltd. or “Netscribes” is not responsible for any loss or damage arising from use of this document. This document is the
sole property of Netscribes (India) Pvt. Ltd. and prior permission is required for guidelines on reproduction.
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 11